keyword
https://read.qxmd.com/read/37980887/endothelin-receptor-blockade-improves-cerebral-blood-flow-mediated-dilation-in-a-mouse-model-of-alzheimer-s-disease
#21
JOURNAL ARTICLE
Daniel Henrion, Philippe Bonnin, Emilie Vessieres, Anne-Laure Guihlot, Marc Iglarz, Bernard I Lévy
INTRODUCTION: Cerebral blood flow (CBF) is reduced in patients with Alzheimer's disease (AD). Flow-mediated dilation (FMD), which plays a key role in the regulation of blood flow, is attenuated by endothelin-1. We hypothesized that endothelin receptor blockade may improve CBF in AD. METHODS: We investigated cerebrovascular reactivity in a mouse model of AD (APP-PS1; 5-6-month-old male subjects). We assessed the in vivo response to normoxic hypercapnia and in vitro FMD in isolated cerebral and mesenteric resistance arteries before and after endothelin receptor blockade (bosentan)...
November 17, 2023: Journal of Vascular Research
https://read.qxmd.com/read/37939680/bosentan-does-not-affect-renal-resistive-index-in-scleroderma-systemic-sclerosis-patients
#22
JOURNAL ARTICLE
Emma Di Poi, GianLuca Colussi, Martina Bertoni, Ivan Giovannini, Barbara Tolusso, Gian Franco Ferraccioli, Elisa Gremese, Salvatore De Vita, Giulio Romano
INTRODUCTION: If properly evaluated, chronic kidney disease can be found in up to 50% of patients with systemic sclerosis (SSc). The renal resistive index (RRI) is a marker of intrarenal vascular resistance and can predict SSc-associated vasculopathy. This study aimed to determine the impact of bosentan, a nonselective endothelin-1 receptor antagonist, on RRI and kidney function in SSc patients with recurrent digital ulcers. METHODS: Twenty-one patients (age 57 ± 9 years, 19 females) were recruited in a 16-week prospective open-label uncontrolled study...
2023: Kidney & Blood Pressure Research
https://read.qxmd.com/read/37915400/kids-mod-pah-trial-a-multicenter-trial-comparing-mono-versus-duo-therapy-for-initial-treatment-of-pediatric-pulmonary-hypertension
#23
JOURNAL ARTICLE
Joseph M Collaco, Steven H Abman, Eric D Austin, Catherine M Avitabile, Angela Bates, Jeffrey R Fineman, Grace A Freire, Stephanie S Handler, Dunbar D Ivy, Usha S Krishnan, Mary P Mullen, Nidhy P Varghese, Delphine Yung, Melanie K Nies, Allen D Everett, Kanecia O Zimmerman, William Simmons, Hrishikesh Chakraborty, Gayane Yenokyan, Allison Newell-Sturdivant, Eric Christensen, Lindsay M Eyzaguirre, Daniel F Hanley, Erika B Rosenzweig, Lewis H Romer
Pulmonary hypertension (PH) is a significant health problem that contributes to high morbidity and mortality in diverse cardiac, pulmonary, and systemic diseases in children. Evidence-based advances in PH care have been challenged by a paucity of quality endpoints for assessing clinical course and the lack of robust clinical trial data to guide pharmacologic therapies in children. While the landmark adult AMBITION trial demonstrated the benefit of up-front combination PH therapy with ambrisentan and tadalafil, it remains unknown whether upfront combination therapy leads to more rapid and sustained clinical benefits in children with various categories of PH...
October 2023: Pulmonary Circulation
https://read.qxmd.com/read/37803134/ultraviolet-photodissociation-and-collision-induced-dissociation-for-qualitative-quantitative-analysis-of-low-molecular-weight-compounds-by-liquid-chromatography-mass-spectrometry
#24
JOURNAL ARTICLE
Romain Giraud, Yves J C Le Blanc, Mircea Guna, Gérard Hopfgartner
Collision-induced dissociation (CID) is the most wildly used fragmentation technique for qualitative and quantitative determination of low molecular weight compounds (LMWC). Ultraviolet photodissociation (UVPD) has been mainly investigated for the analysis of peptides and lipids while only in a limited way for LMWC. A triple quadrupole linear ion trap instrument has been modified to allow ultraviolet photodissociation (UVPD) in the end of the q2 region enabling various workflows with and without data-dependent acquisition (DDA) combining CID and UVPD in the same LC-MS analysis...
October 7, 2023: Analytical and Bioanalytical Chemistry
https://read.qxmd.com/read/37765060/recent-advances-in-the-treatment-of-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases
#25
REVIEW
Anna Smukowska-Gorynia, Weronika Gościniak, Patrycja Woźniak, Sylwia Iwańczyk, Karolina Jaxa-Kwiatkowska, Sylwia Sławek-Szmyt, Magdalena Janus, Jerzy Paluszkiewicz, Tatiana Mularek-Kubzdela
Pulmonary hypertension (PH) is a severe vascular complication of connective tissue diseases (CTD). Patients with CTD may develop PH belonging to diverse groups: (1) pulmonary arterial hypertension (PAH), (2) PH due to left heart disease, (3) secondary PH due to lung disease and/or hypoxia and (4) chronic thromboembolic pulmonary hypertension (CTEPH). PAH most often develops in systemic scleroderma (SSc), mostly in its limited variant. PAH-CTD is a progressive disease characterized by poor prognosis. Therefore, early diagnosis should be established...
September 5, 2023: Pharmaceuticals
https://read.qxmd.com/read/37762589/the-pathogenesis-of-systemic-sclerosis-the-origin-of-fibrosis-and-interlink-with-vasculopathy-and-autoimmunity
#26
REVIEW
Junsuk Ko, Maria Noviani, Vasuki Ranjani Chellamuthu, Salvatore Albani, Andrea Hsiu Ling Low
Systemic sclerosis (SSc) is an autoimmune disease associated with increased mortality and poor morbidity, impairing the quality of life in patients. Whilst we know that SSc affects multiple organs via vasculopathy, inflammation, and fibrosis, its exact pathophysiology remains elusive. Microvascular injury and vasculopathy are the initial pathological features of the disease. Clinically, the vasculopathy in SSc is manifested as Raynaud's phenomenon (reversible vasospasm in reaction to the cold or emotional stress) and digital ulcers due to ischemic injury...
September 19, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37654961/current-status-of-endothelin-receptor-antagonists-in-pulmonary-arterial-hypertension-a-combined-study-results-and-pharmacology-based-review
#27
REVIEW
Shamsun Nahar, Srishti Kanda, Uzair Chatha, Victor A Odoma, Aakanksha Pitliya, Esraa M AlEdani, Japneet K Bhangu, Khalid Javed, Prabhleen Kaur Manshahia, Ann Kashmer Yu
Pulmonary arterial hypertension (PAH) affects a wide range of people globally and has a poor prognosis despite many advancements in available treatment options. Among the available treatments, endothelin receptor antagonists (ERA) are among the most widely used drugs. These drugs have been evaluated in scientific trials. We included free full texts in the English language from the last ten years and reviewed them. We are writing this review to amalgamate the pharmacological aspects and the previous studies on ERAs to demonstrate a comprehensive overview of the current status of ERAs for PAH treatment...
July 2023: Curēus
https://read.qxmd.com/read/37554128/bosentan-for-high-risk-outpatients-with-covid-19-infection-a-randomized-double-blind-placebo-controlled-trial
#28
JOURNAL ARTICLE
Shaahin Shahbazi, Zahra Vahdat Shariatpanahi, Erfan Shahbazi
BACKGROUND: The endothelium is supposedly activated and damaged in COVID-19 because of endothelin-1 over-secretion. This study evaluates the effect of bosentan as an endothelin receptor blocker on the progression of disease in high-risk outpatients with COVID-19 infection. METHODS: From 15 December 2021 to 15 May 2022, high-risk outpatients were randomly assigned to receive bosentan, 62.5 mg or placebo twice daily from enrollment for 30 days. Both groups received standard medical treatment too...
August 2023: EClinicalMedicine
https://read.qxmd.com/read/37515921/development-of-novel-bosentan-analogues-as-endothelin-receptor-antagonists-for-pulmonary-arterial-hypertension
#29
JOURNAL ARTICLE
Jigar Panchal, Shivangi Jaiswal, Sonika Jain, Jyoti Kumawat, Ashima Sharma, Pankaj Jain, Smita Jain, Kanika Verma, Jaya Dwivedi, Swapnil Sharma
Since decades, bosentan has been in use for the treatment of pulmonary arterial hypertension (PAH). However, chronic exposure to bosentan leads to the development of resistance, tolerance, and serious adverse effects that have restricted its usage in clinical practices. To surmount these limitations, some new bosentan derivatives have been synthesized and evaluated for their therapeutic efficacy in PAH. Molecular docking analyses of all the synthesized derivatives were carried out using the endothelin (ET) receptor...
July 25, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/37457231/pharmacogenomics-in-the-management-of-pulmonary-arterial-hypertension-current-perspectives
#30
REVIEW
James C Coons, Philip E Empey
Pulmonary arterial hypertension (PAH) is a rare disease with heterogeneous causes that can lead to right ventricular (RV) failure and death if left untreated. There are currently 10 medications representative of five unique pharmacologic classes that are approved for treatment. These have led to significant improvements in overall clinical outcome. However, substantial variability in dosing requirements and treatment response is evident, leading to suboptimal outcome for many patients. Furthermore, dosing is empiric and iterative and can lead to delays in meeting treatment goals and burdensome adverse effects...
2023: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/37433349/development-and-pharmacokinetic-evaluation-of-neusilin%C3%A2-us2-based-s-snedds-tablets-for-bosentan-fasted-and-fed-states-bioavailability-ivis%C3%A2-real-time-biodistribution-and-ex-vivo-imaging
#31
JOURNAL ARTICLE
Duygu Yilmaz Usta, Seval Olgac, Burcu Timur, Zeynep Safak Teksin
The study reported here aimed to develop and optimize the S-SNEDDS tablet of bosentan (BOS) and to investigate its pharmacokinetic and biodistribution properties. The BOS-loaded SNEDDS have been developed and characterized in a previous study. The BOS-loaded SNEDDS formulation was converted to S-SNEDDS using Neusilin® US2. The S-SNEDDS tablets were obtained using the direct compression technique, and in vitro dissolution, in vitro lipolysis, and ex-vivo permeability studies of the tablets were performed...
July 9, 2023: International Journal of Pharmaceutics
https://read.qxmd.com/read/37407092/a-20-year-research-overview-quantitative-prediction-of-hepatic-clearance-using-the-in-vitro-in-vivo-extrapolation-approach-based-on-physiologically-based-pharmacokinetic-modeling-and-extended-clearance-concept
#32
REVIEW
Yuichi Sugiyama, Yasunori Aoki
Understanding the extended clearance concept and establishing a physiologically based pharmacokinetic (PBPK) model are crucial for investigating the impact of changes in transporter and metabolizing enzyme abundance/functions on drug pharmacokinetics in blood and tissues. This mini-review provides an overview of the extended clearance concept and a PBPK model that includes transporter-mediated uptake processes in the liver. In general, complete in vitro and in vivo extrapolation (IVIVE) poses challenges due to missing factors that bridge the gap between in vitro and in vivo systems...
September 2023: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://read.qxmd.com/read/37403496/cost-utility-of-ambrisentan-and-bosentan-for-pediatric-pulmonary-arterial-hypertension
#33
JOURNAL ARTICLE
Jefferson Antonio Buendia, Diana Guerrero Patino, Erika Fernanda Lindarte
INTRODUCTION: Despite the increasing evidence supporting the efficacy of ambrisentan and bosentan in improving functional classes among pediatric patients with pulmonary arterial hypertension (PAH), there is a lack of information regarding their cost implications. Therefore, the objective of this study is to assess the cost-utility of bosentan compared to ambrisentan for the treatment of pediatric patients with PAH in Colombia. METHODS: We employed a Markov model to estimate the costs and quality-adjusted life-years (QALYs) associated with the use of ambrisentan or bosentan in pediatric patients diagnosed with pulmonary arterial hypertension (PAH)...
July 5, 2023: Expert Review of Pharmacoeconomics & Outcomes Research
https://read.qxmd.com/read/37335850/systemic-pharmacological-treatment-of-digital-ulcers-in-systemic-sclerosis-a-systematic-literature-review
#34
JOURNAL ARTICLE
Laura Ross, Nancy Maltez, Michael Hughes, Jan W Schoones, Murray Baron, Lorinda Chung, Dilia Giuggioli, Pia Moinzadeh, Yossra A Suliman, Corrado Campochiaro, Yannick Allanore, Christopher P Denton, Oliver Distler, Tracy Frech, Daniel E Furst, Dinesh Khanna, Thomas Krieg, Masataka Kuwana, Marco Matucci-Cerinic, Janet Pope, Alessia Alunno
OBJECTIVES: To evaluate the evidence concerning systemic pharmacological treatments for systemic sclerosis (SSc) digital ulcers (DU) to inform the development of evidence-based treatment guidelines. METHODS: A systematic literature review of seven databases was performed to identify all original research studies of adult patients with SSc DU. Randomised controlled trials (RCTs) and prospective longitudinal observational studies (OBS) were eligible for inclusion...
June 19, 2023: Rheumatology
https://read.qxmd.com/read/37255911/macitentan-for-the-treatment-of-refractory-digital-ulcers-in-patients-with-connective-tissue-diseases
#35
JOURNAL ARTICLE
Clara Soto Abánades, Ana Noblejas Mozo, Gema Bonilla Hernán, Jorge Alvarez Troncoso, Juan José Ríos Blanco
Systemic sclerosis (SSc) is a chronic autoimmune disease with complex pathogenesis, characterized by vascular dysfunction and fibrosis. Digital ulcers (DUs) are a common and severe complication in SSc patients, negatively impacting their quality of life. This retrospective study evaluates the use of macitentan, an endothelin receptor antagonist, in six female patients with connective tissue disease (CTD) and sclerodermiform features (five SSc and one mixed connective tissue disease) for the treatment of refractory DUs...
April 2023: Curēus
https://read.qxmd.com/read/37245698/prescribing-of-endothelin-receptor-antagonists-and-riociguat-in-women-of-childbearing-age-in-a-large-german-claims-database-study
#36
JOURNAL ARTICLE
Ute Amann, Nadine Wentzell, Bianca Kollhorst, Ulrike Haug
Use of endothelin receptor antagonists (ERAs) and riociguat, approved for treatment of pulmonary hypertension (PH), is contraindicated during pregnancy due to reported teratogenicity in animals. We aimed to investigate prescribing of these drugs in girls/women of childbearing age and to explore - as a secondary aim - the occurrence of pregnancies exposed to these drugs. Using the German Pharmacoepidemiological Research Database (GePaRD, claims data from 20% of the German population) we conducted cross-sectional analyses to determine prescribing prevalence of ERAs and riociguat between 2004 and 2019 and to characterize users and prescribing patterns...
May 26, 2023: Reproductive Toxicology
https://read.qxmd.com/read/37218926/growing-up-with-idiopathic-pulmonary-arterial-hypertension-an-arduous-journey
#37
Tanguy Dutilleux, Nesrine Farhat, Ruth Heying, Marie-Christine Seghaye, Maurice Beghetti
Idiopathic pulmonary arterial hypertension (IPAH) is an uncommon and severe disease. We report the case of a 7-year-old boy investigated for cardiac murmur and exercise intolerance. Pulmonary hypertension (PH) was suspected at clinical examination and confirmed by echocardiography and cardiac catheterization. This case of pulmonary hypertension was classified as idiopathic given the negative etiological investigation. Vasoreactive testing with oxygen and nitric oxide was negative. Therefore, treatment with sildenafil (1...
May 5, 2023: Pediatric Reports
https://read.qxmd.com/read/37196874/high-energy-ball-milling-vs-nano-spray-drying-in-the-development-of-supersaturated-systems-loaded-with-bosentan
#38
JOURNAL ARTICLE
Anna Krupa, Florence Danède, Dorota Majda, Agnieszka Węgrzyn, Dominik Strojewski, Ita Kondera, Jean-François Willart
In this study, high energy ball milling and nano spray drying were used to prepare amorphous solid dispersions of bosentan in copovidone for the first time. In particular, the impact of this polymer on the bosentan amorphization kinetics was investigated. Copovidone was shown to facilitate the amorphization of bosentan upon ball milling. As a result, bosentan was dispersed in copovidone at the molecular level, forming amorphous solid dispersions, regardless of the ratio of the compounds. The similarity between the values of the adjustment parameter that describes the goodness of fit of the Gordon-Taylor equation to the experimental data (K = 1...
May 15, 2023: European Journal of Pharmaceutics and Biopharmaceutics
https://read.qxmd.com/read/37088122/loss-of-ceacam1-in-endothelial-cells-causes-hepatic-fibrosis
#39
JOURNAL ARTICLE
Harrison T Muturi, Hilda E Ghadieh, Raziyeh Abdolahipour, Hannah L Stankus, Getachew Debas Belew, James K Liu, Marziyeh Salehi Jahromi, Abraham D Lee, Bernhard B Singer, Isabella Angeli-Pahim, Tejasav S Sehrawat, Harmeet Malhi, Stefaan Verhulst, Leo A van Grunsven, Ali Zarrinpar, Sergio Duarte, Sonia M Najjar
OBJECTIVES: Hepatocytic CEACAM1 plays a critical role in NASH pathogenesis, as bolstered by the development of insulin resistance, visceral obesity, steatohepatitis and fibrosis in mice with global Ceacam1 (Cc1) deletion. In contrast, VECadCre+Cc1fl/fl mice with endothelial loss of Cc1 manifested insulin sensitivity with no visceral obesity despite elevated NF-κB signaling and increased systemic inflammation. We herein investigated whether VECadCre+Cc1fl/fl male mice develop hepatic fibrosis and whether this is mediated by increased production of endothelin1 (ET1), a transcriptional NF-κB target...
April 21, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/36986758/use-of-in-vivo-imaging-and-physiologically-based-kinetic-modelling-to-predict-hepatic-transporter-mediated-drug-drug-interactions-in-rats
#40
JOURNAL ARTICLE
Nicola Melillo, Daniel Scotcher, J Gerry Kenna, Claudia Green, Catherine D G Hines, Iina Laitinen, Paul D Hockings, Kayode Ogungbenro, Ebony R Gunwhy, Steven Sourbron, John C Waterton, Gunnar Schuetz, Aleksandra Galetin
Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2. Six drugs, with varying degrees of transporter inhibition, were used to assess gadoxetate dynamic contrast enhanced MRI biomarkers for transporter inhibition in rats. Prospective prediction of changes in gadoxetate systemic and liver AUC (AUCR), resulting from transporter modulation, were performed by physiologically-based pharmacokinetic (PBPK) modelling...
March 10, 2023: Pharmaceutics
keyword
keyword
11367
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.